A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

被引：0
|
作者：
Laura Q. M. Chow
S. Gail Eckhardt
Cindy L. O’Bryant
Mary Kay Schultz
Mark Morrow
Stacy Grolnic
Michele Basche
Lia Gore
机构：
[1] University of Colorado Cancer Center,
[2] The Children’s Hospital,undefined
[3] University of Colorado Health Sciences Center at Fitzsimons,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 62卷
关键词：
Lonafarnib; SCH66336; Cisplatin; Gemcitabine; Farnesyltransferase; Phase I; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：631 / 646
页数：15
相关论文
共 50 条
  • [31] Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors
    Joleen Hubbard
    Charles Erlichman
    David O. Toft
    Rui Qin
    Bridget A. Stensgard
    Sara Felten
    Cynthia Ten Eyck
    Gretchen Batzel
    S. Percy Ivy
    Paul Haluska
    Investigational New Drugs, 2011, 29 : 473 - 480
  • [32] Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors
    Calvo, Emiliano
    Braiteh, Fadi
    Von Hoff, Daniel
    McWilliams, Robert
    Becerra, Carlos
    Galsky, Matthew D.
    Jameson, Gayle
    Lin, Ji
    McKane, Scott
    Wickremsinhe, Enaksha R.
    Hynes, Scott M.
    Lin, Aimee Bence
    Hurt, Karla
    Richards, Donald
    ONCOLOGY, 2016, 91 (05) : 251 - 260
  • [33] Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
    Ryan, David P.
    Appleman, Leonard J.
    Lynch, Thomas
    Supko, Jeffrey G.
    Fidias, Panagiotis
    Clark, Jeffrey W.
    Fishman, Mayer
    Zhu, Andrew X.
    Enzinger, Peter C.
    Kashala, Oscar
    Cusack, James, Jr.
    Eder, Joseph P.
    CANCER, 2006, 107 (10) : 2482 - 2489
  • [34] Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
    Edward Sausville
    Patricia LoRusso
    Michael Carducci
    Judith Carter
    Mary F. Quinn
    Lisa Malburg
    Nilofer Azad
    David Cosgrove
    Richard Knight
    Peter Barker
    Sonya Zabludoff
    Felix Agbo
    Patricia Oakes
    Adrian Senderowicz
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 539 - 549
  • [35] Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
    Sausville, Edward
    LoRusso, Patricia
    Carducci, Michael
    Carter, Judith
    Quinn, Mary F.
    Malburg, Lisa
    Azad, Nilofer
    Cosgrove, David
    Knight, Richard
    Barker, Peter
    Zabludoff, Sonya
    Agbo, Felix
    Oakes, Patricia
    Senderowicz, Adrian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 539 - 549
  • [36] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    Kim, R. D.
    Alberts, S. R.
    Pena, C.
    Genvresse, I.
    Ajavon-Hartmann, A.
    Xia, C.
    Kelly, A.
    Grilley-Olson, J. E.
    BRITISH JOURNAL OF CANCER, 2018, 118 (04) : 462 - 470
  • [37] A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
    Mortazavi, Amir
    Ling, Yonghua
    Martin, Ludmila Katherine
    Wei, Lai
    Phelps, Mitch A.
    Liu, Zhongfa
    Harper, Erica J.
    Ivy, S. Percy
    Wu, Xin
    Zhou, Bing-Sen
    Liu, Xiyong
    Deam, Deidre
    Monk, J. Paul
    Hicks, William J.
    Yen, Yun
    Otterson, Gregory A.
    Grever, Michael R.
    Bekaii-Saab, Tanios
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) : 685 - 695
  • [38] A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
    Amir Mortazavi
    Yonghua Ling
    Ludmila Katherine Martin
    Lai Wei
    Mitch A. Phelps
    Zhongfa Liu
    Erica J. Harper
    S. Percy Ivy
    Xin Wu
    Bing-Sen Zhou
    Xiyong Liu
    Deidre Deam
    J. Paul Monk
    William J. Hicks
    Yun Yen
    Gregory A. Otterson
    Michael R. Grever
    Tanios Bekaii-Saab
    Investigational New Drugs, 2013, 31 : 685 - 695
  • [39] A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumors
    Schelman, William R.
    Morgan-Meadows, Sherry
    Marnocha, Rebecca
    Lee, Fred
    Eickhoff, Jens
    Huang, Wei
    Pomplun, Marcia
    Jiang, Zhisheng
    Alberti, Dona
    Kolesar, Jill M.
    Ivy, Percy
    Wilding, George
    Traynor, Anne M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (06) : 1147 - 1156
  • [40] Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors
    Emily Chan
    E. Gabriela Chiorean
    Peter J. O’Dwyer
    Nashat Y. Gabrail
    Thierry Alcindor
    Diane Potvin
    Richard Chao
    Herbert Hurwitz
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 355 - 364
12345